Oxylan Depot 20 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

oxylan depot 20 mg depottabletter

g.l. pharma gmbh - oxycodonhydrochlorid - depottabletter - 20 mg

Oxylan Depot 40 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

oxylan depot 40 mg depottabletter

g.l. pharma gmbh - oxycodonhydrochlorid - depottabletter - 40 mg

Oxylan Depot 80 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

oxylan depot 80 mg depottabletter

g.l. pharma gmbh - oxycodonhydrochlorid - depottabletter - 80 mg

Oxylan Depot 5 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

oxylan depot 5 mg depottabletter

g.l. pharma gmbh - oxycodonhydrochlorid - depottabletter - 5 mg

Depolan 60 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 60 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 60 mg

Lannate 20 L Flydende middel Danemark - danois - SEGES Landbrug & Fødevarer

lannate 20 l flydende middel

du pont danmark aps - methomyl - flydende middel - 200 g/l methomyl

Lannate 25 WP Vanddispergerbart pulver Danemark - danois - SEGES Landbrug & Fødevarer

lannate 25 wp vanddispergerbart pulver

du pont danmark aps - methomyl - vanddispergerbart pulver - 250 g/kg methomyl

Depolan 100 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 100 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 100 mg

Depolan 10 mg depottabletter Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

depolan 10 mg depottabletter

g.l. pharma gmbh - morphinhydrochloridtrihydrat - depottabletter - 10 mg

Celsunax Union européenne - danois - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne patienter, til at hjælpe med at differentiere sandsynligt, demens med lewy organer fra alzheimers sygdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.